GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosergen AB (OSTO:BIOSGN) » Definitions » EV-to-FCF

Biosergen AB (OSTO:BIOSGN) EV-to-FCF : -0.91 (As of Jun. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biosergen AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biosergen AB's Enterprise Value is kr42.19 Mil. Biosergen AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was kr-46.59 Mil. Therefore, Biosergen AB's EV-to-FCF for today is -0.91.

The historical rank and industry rank for Biosergen AB's EV-to-FCF or its related term are showing as below:

OSTO:BIOSGN' s EV-to-FCF Range Over the Past 10 Years
Min: -8.31   Med: -4.65   Max: 0.04
Current: -1.02

During the past 4 years, the highest EV-to-FCF of Biosergen AB was 0.04. The lowest was -8.31. And the median was -4.65.

OSTO:BIOSGN's EV-to-FCF is ranked worse than
100% of 397 companies
in the Biotechnology industry
Industry Median: 6.42 vs OSTO:BIOSGN: -1.02

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-21), Biosergen AB's stock price is kr0.308. Biosergen AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.281. Therefore, Biosergen AB's PE Ratio for today is At Loss.


Biosergen AB EV-to-FCF Historical Data

The historical data trend for Biosergen AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosergen AB EV-to-FCF Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -3.46 -0.52 -1.30

Biosergen AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.01 -1.23 -1.30 -0.78

Competitive Comparison of Biosergen AB's EV-to-FCF

For the Biotechnology subindustry, Biosergen AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosergen AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosergen AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Biosergen AB's EV-to-FCF falls into.



Biosergen AB EV-to-FCF Calculation

Biosergen AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=42.186/-46.591
=-0.91

Biosergen AB's current Enterprise Value is kr42.19 Mil.
Biosergen AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-46.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosergen AB  (OSTO:BIOSGN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Biosergen AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.308/-0.281
=At Loss

Biosergen AB's share price for today is kr0.308.
Biosergen AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.281.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Biosergen AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Biosergen AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosergen AB (OSTO:BIOSGN) Business Description

Traded in Other Exchanges
N/A
Address
Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.

Biosergen AB (OSTO:BIOSGN) Headlines

No Headlines